Skip to content
★ Sign in to follow
Insider activity · 24 months3 buys0 salesCumulative net flow
Total declarations
3
Company
1
▲ Purchases (3 ops.)
€213k
▼ Sales (0 ops.)
—

Latest filing published 22 Oct 2026 for Rapport Therapeutics, Inc., €89k.

Filing timeline

BuySale
Wendy B. Young

Insider track record

Disclosed buys
3
Disclosed sells
0
Signal history

Closed purchases

Market purchases
3
Positive at T+90
100%
Median T+90
+13.6%

Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Wendy B. Young: trading record in brief

Wendy B. Young discloses dealings in Rapport Therapeutics, Inc. to SEC (Form 4). The record holds 3 filings, for trades running from 12 March 2025 to 22 October 2026.

On the market, this insider has only ever bought: 3 purchases, €213k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2026, the count stands at 1 purchase and no sales.

The median purchase comes to €67k. Clusters matter here: 2 out of 3 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 22 October 2026 with an open-market purchase (€89k) in Rapport Therapeutics, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.

Companies and markets linked to Wendy B. Young

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations3 total
  • ▲
    DirectorExecutivesRapport Therapeutics, Inc.
    99,992 USD42SEC
    3,789 shares@ US$26.390.0071% mcap41.9% of flowCommon StockSEC:0001193125-26-429074:0
    Canonical exit: 20 Jan 2027 (T+90)
  • ▲
    DirectorExecutivesRapport Therapeutics, Inc.
    79,100 USD18SEC
    3,500 shares@ US$22.6054.6% of flowCommon StockSEC:0000950170-25-114325:0
    Canonical exit: 10 Dec 2025 (T+90)
  • ▲
    DirectorExecutivesRapport Therapeutics, Inc.
    61,250 USD28SEC
    6,000 shares@ US$10.208345.4% of flowCommon StockSEC:0000950170-25-038855:0
    Canonical exit: 10 Jun 2025 (T+90)

3 of 3 declarations